Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2026
Pharma News, 2026
NewAmsterdam Pharma Starts Phase 2b Trial of Obicetrapib in Alzheimer’s
NewAmsterdam Pharma has dosed its first patient in the Phase 2b SPINOZA trial to evaluate Obicetrapib in adults with preclinical Alzheimer’s disease.
Clinical Trials Struggle to Recruit Undiagnosed Patients Without Coverage
Clinical trials face major operational challenges in recruiting patients with rare, undiagnosed conditions due to a lack of diagnostic testing coverage.
Immix’s NXC-201 achieves 89% complete response rate in AL amyloidosis trial
Immix Biopharma announced an 89% complete response rate for its BCMA-targeted CAR-T cell therapy NXC-201 in a Phase 2 trial for relapsed AL amyloidosis.
FDA recalls thousands more bottles of blood pressure meds due to issues
The FDA has issued a second recall this year for thousands of bottles of Chlorthalidone blood pressure tablets because the pills do not dissolve properly.
SK pharmteco Announces $200-Plus Million U.S. Investment in Small Molecule
SK pharmteco unveils a $200M+ investment plan to expand and upgrade its U.S. development and manufacturing infrastructure for small molecules and peptides.
FDA nod for Mirum’s Atebrioz makes 3 options for ultra-rare bone disease
The FDA approved Mirum Pharmaceuticals' Atebrioz for fibrodysplasia ossificans progressiva, offering a crucial third treatment for the rare bone condition.
Caspian Therapeutics and Kura Oncology Report Preclinical Data for Diabetes Candidate KO-7246
Caspian Therapeutics and Kura Oncology presented promising preclinical data for KO-7246, an oral menin inhibitor showing potential in diabetes models.
Swiss groups seek reforms as clinical trial numbers fall
The Swiss Cancer Institute and Interpharma urge reforms as clinical trials in Switzerland plummet by over 25% in ten years, threatening patient access.
Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor
Merck strikes a potential $2.13 billion licensing deal with SciBrunch Therapeutics for SPR2015, an oral preclinical KRAS inhibitor for solid tumors.
Hanall's New Drug Value Put at 3.67 Trillion Won Despite Trial Setback
Hanall Biopharma halts development of IMVT-1402 for cutaneous lupus, but its overall $2.6B valuation holds due to promise in other autoimmune indications.
US FDA approves AbbVie's drug for Parkinson's disease treatment in adults
The US FDA has approved AbbVie's once-a-day pill, Juvmo (tavapadon), for the treatment of Parkinson's disease in adults to improve movement control.
First results from funded preclinical study into probucol and chlorogenic
A Cure Parkinson’s funded project has published results showing that chlorogenic acid does not have a neuroprotective effect in Parkinson’s disease models.
1
2
3
4
5
